0001140361-15-022956.txt : 20150602 0001140361-15-022956.hdr.sgml : 20150602 20150602202426 ACCESSION NUMBER: 0001140361-15-022956 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150529 FILED AS OF DATE: 20150602 DATE AS OF CHANGE: 20150602 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Relypsa Inc CENTRAL INDEX KEY: 0001416792 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260893742 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CARDINAL WAY CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-421-9500 MAIL ADDRESS: STREET 1: 100 CARDINAL WAY CITY: REDWOOD CITY STATE: CA ZIP: 94063 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Orwin John A CENTRAL INDEX KEY: 0001477384 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36184 FILM NUMBER: 15908544 MAIL ADDRESS: STREET 1: C/O RELYPSA, INC. STREET 2: 700 SAGINAW DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc1.xml FORM 4 X0306 4 2015-05-29 0 0001416792 Relypsa Inc RLYP 0001477384 Orwin John A C/O RELYPSA, INC. 100 CARDINAL WAY REDWOOD CITY CA 94063 1 1 0 0 President & CEO Common Stock 2015-05-29 4 M 0 20000 7.40 A 55000 D Common Stock 2015-05-29 4 S 0 14694 36.3953 D 40306 D Common Stock 2015-05-29 4 S 0 5306 36.9786 D 35000 D Common Stock 2015-06-01 4 M 0 8555 7.4 A 43555 D Common Stock 2015-06-01 4 S 0 8351 35.7913 D 35204 D Common Stock 2015-06-01 4 S 0 5204 36.9437 D 30000 D Stock Option (right to buy) 7.40 2015-05-29 4 M 0 20000 0.00 D 2023-07-23 Common Stock 20000 811432 D Stock Option (right to buy) 7.40 2015-06-01 4 M 0 8555 0.00 D 2023-07-23 Common Stock 8555 802877 D Includes 20,000 restricted stock units. The sales reported in this Form 4 were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.79 to $36.78, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.79 to $37.18, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The shares subject to the option are early exercisable. 25% of the shares subject to the option vest on the first anniversary measured from June 17, 2013 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $35.35 to $36.3327, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.35 to $37.29, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. /s/ Ronald A. Krasnow, as Attorney-in-Fact for John A. Orwin 2015-06-02